Next Article in Journal
Analysis of Parents’ Attitudes and Knowledge toward Immunization and How These Factors Influence Their Decisions to Vaccinate Their Children against Human Papilloma Virus (HPV)
Next Article in Special Issue
Does Early Mobilization Following Resection of Spinal Intra-Dural Pathology Increase the Risk of Cerebrospinal Fluid Leaks?—A Dual-Center Comparative Effectiveness Research
Previous Article in Journal
Common Skin Diseases and Their Psychosocial Impact among Jazan Population, Saudi Arabia: A Cross-Sectional Survey during 2023
Previous Article in Special Issue
Minimally Invasive Facetectomy and Fusion for Resection of Extensive Dumbbell Tumors in the Lumbar Spine
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Neurological Outcome and Respiratory Insufficiency in Intramedullary Tumors of the Upper Cervical Spine

by
Kateryna Goloshchapova
*,
Maria Goldberg
,
Bernhard Meyer
,
Maria Wostrack
and
Vicki M. Butenschoen
Department of Neurosurgery, Klinikum rechts der Isar, Technical University of Munich, 81675 Munich, Germany
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Medicina 2023, 59(10), 1754; https://doi.org/10.3390/medicina59101754
Submission received: 30 June 2023 / Revised: 21 September 2023 / Accepted: 27 September 2023 / Published: 30 September 2023
(This article belongs to the Special Issue Spinal Tumors)

Abstract

:
Background and Objectives: Intramedullary spinal cord tumors (IMSCT) are rare entities. A location in the upper cervical spine as a highly eloquent region carries the risk of postoperative neurological deficits, such as tetraparesis or respiratory dysfunction. Evidence for respiratory dysfunction is scarce. This study aimed to describe these highly eloquent tumors’ early and late postoperative clinical course. Materials and Methods: This is a single-center retrospective cohort study. We included 35 patients with IMSCT at levels of the craniocervical junction to C4 who underwent surgical treatment between 2008 and 2022. The authors analyzed the patients’ preoperative status, tumor- and surgery-specific characteristics, and follow-up functional status. Results: The study cohort included twenty-two patients with grade II ependymoma (62.9%), two low-grade astrocytomas (5.7%), two glioblastomas (5.7%), six hemangioblastomas (17.1%), two metastases (5.7%), and one patient with partially intramedullary schwannoma (2.9%). Gross total resection was achieved in 76% of patients. Early dorsal column-related symptoms (gait ataxia and sensory loss) and motor deterioration occurred in 64% and 44% of patients. At a follow-up of 3.27 ± 3.83 years, 43% and 33% of patients still exhibited postoperative sensory and motor deterioration, respectively. The median McCormick Scale grade was 2 in the preoperative and late postoperative periods, respectively. Only three patients (8.6%) developed respiratory dysfunction, of whom, two patients, both with malignant IMSCT, required prolonged invasive ventilation. Conclusions: More than 60% of the patients with IMSCT in the upper cervical cord developed new neurological deficits in the immediate postoperative period, and more than 40% are permanent. However, these deficits are not disabling in most cases since most patients maintain functional independence as observed by unchanged low McCormick scores. The rate of respiratory insufficiency is relatively low and seems to be influenced by the rapid neurological deterioration in high-grade tumors.

1. Introduction

Intramedullary spinal cord tumors (IMSCT) are rare entities and account for only 5–10% of all spinal tumors. The most frequent entities are ependymomas, astrocytomas, and hemangioblastomas [1]. Patients with low-grade tumors usually present with mild neurological deficits such as gait ataxia, hypesthesia, or pain. The optimal treatment for IMSCT depends on the tumor type. For most IMSCT, the standard therapy is the surgical gross total resection (GTR), although it bears a risk for neurological deterioration [2,3]. The GTR is the main predictor of progression-free survival in benign or low-grade entities [4]. The GTR results in a more prolonged progression-free survival with an excellent neurological long-term outcome for ependymomas, hemangioblastomas, and pilocytic astrocytomas [3]. However, for high-grade astrocytomas, surgical resection does not provide any oncological benefit, is often not feasible, and comes along with a high rate of neurological impairment; therefore, usually a biopsy with adjuvant chemo- or radiotherapy is the commonly accepted approach [5].
The most commonly affected site of IMSCT is the cervical spine [3]. Especially their location in the upper cervical spine, i.e., the craniocervical junction downwards, up to the level of C4 or C5, carries the highest risk for postoperative neurological deficits resulting in a tetraparesis—a devastating disability condition. Additionally, surgical treatment may result in respiratory failure due to the innervation of the diaphragm by the C3-5 nerve roots. Further, tumor mass extending into the medulla oblongata can aggravate respiratory dysfunction. This problem is commonly known in patients who experienced traumatic spinal cord injury [6]. However, there is little evidence of this complication in patients who undergo surgery for IMSCT. We are hereby investigating the surgical risks of intramedullary tumor surgery in the upper spine with particular emphasis on respiratory failure.

2. Patients and Methods

We conducted a retrospective cohort study of patients who underwent surgical resection of IMSCT above or at the C4 level from January 2008 to December 2022 at our tertiary care institution.

2.1. Surgery Protocol and Postoperative Management

Microsurgical techniques with continuous neuromonitoring were used in all cases. Patients were placed in a prone position with a rigid head fixation in the Mayfield clamp. The most common approach was laminoplasty (57%), followed by a durotomy and median myelotomy in most cases. For tumors near the surface of the spinal cord, we used either the transpial method or the dorsal root entry zone technique. Tumor debulking using a cavitron ultrasound surgical aspirator (CUSA) was applied in more extensive tumors (excluding hemangioblastomas) before the final tumor removal to minimize traction damage to the spinal cord tissue. We did not use intraoperative ultrasound for imaging purposes.
The local multidisciplinary tumor board decided on surgical and adjuvant treatment. High-grade astrocytomas received fractional radiation therapy with a total 40–60 Gy dose in 1.8 to 2-Gy fractions with or without Temozolomide therapy. Patients with ependymomas and hemangioblastomas underwent follow-up examinations every 12 months.

2.2. Medical and Surgical Data

All patients had preoperative contrast-enhanced magnetic resonance imaging (MRI) of the spinal cord to evaluate the tumor location, size, and extent. The tumor volume was calculated using the formula for ellipsoid: 4/3 × π × ABC/2, where A, B, and C are the length of semi-axes. We also assessed the presence of syrinx on the preoperative MRI scan.
The surgery-specific information included the extent of resection (GTR defined as complete removal of the contrast-enhancing tumor, subtotal resection (STR) defined as removal of more than 90% of the contrast-enhancing tumor, tumor debulking, or biopsy), as well as the intraoperative changes in recordings of the intraoperative neuromonitoring. The surgical approach was subclassified as unilateral (interlaminar fenestration or hemilaminectomy) or bilateral (laminoplasty and laminectomy), depending on tumor extent and tumor location within the spinal canal.
In our cases, tumor histology was defined according to the current WHO classification, congruent with the WHO 2021 classification. The preoperative neurological status was evaluated. The outcome was assessed at discharge and the most recent follow-up. We used the modified McCormick scale to determine the clinical status of the patients, which is a widely accepted tool for neurological grading function in spinal cord tumors [7]. We also recorded any postoperative neurological worsening, such as new motor deficit defined with the Medical Research Council classification (MRC), hypesthesia, aggravation of gait ataxia, or respiratory insufficiency, which required postoperative intubation, prolonged weaning, or respiratory tract infections.
The patients underwent a follow-up MRI three months after the surgery and had yearly imaging and clinical examinations afterward as long as their clinical and neurological status remained stable. In cases of hemangioblastoma, further examinations to rule out Von Hippel-Lindau syndrome were conducted.

2.3. Statistical Analysis

Statistical analyses were performed using Microsoft Excel (Version 2019) and StatTech v. 3.1.6. (Developer—StatTech LLC, Moscow, Russia). The median or mean values were compared using the Student t-test. The correlation between potential predictive factors and the transient and permanent neurologic deficit was analyzed with a chi-square test for the categorical variables such as sex, the extent of resection, presence of syrinx, WHO grade, tumor entity, and preoperative McCormick scale. For continuous variables such as tumor volume, age, and duration of symptoms, the Kruskal–Wallis test was utilized.

3. Results

3.1. Entities and Presentation

We included 35 consecutive patients who underwent a surgical treatment protocol; 57% of patients were male with a mean age of 45 ± 16 years. The mean duration of symptoms before the intervention was 22 ± 48 months. Patients with high-grade tumors (metastasis and high-grade astrocytomas) had a significantly shorter symptom duration than those with low-grade counterparts (p = 0.012). The median follow-up period was 3.27 ± 3.83 years and was available for 29 patients (83%).
The most common type of tumor was ependymoma WHO°2, which affected twenty-two patients (62.9%), followed by astrocytoma WHO°2–4 in four patients (11.4%), hemangioblastoma WHO°1 in six patients (17.1%), and carcinoma metastasis (adenocarcinoma of colon cancer and melanoma metastasis) in two patients (5.7%). Four patients (11.4%) had a clinical diagnosis of neurofibromatosis type 2. Two patients (5.7%) had recurrent tumors at the same level, and two patients (5.7%) had drop metastasis of ependymomas at different levels from the upper cervical spine (Table 1).
The tumor extension ranged from 1 to 9 segments, with a mean of 2.8. The mean tumor volume was 1.86 ± 2.58 cm3. Syringomyelia was found in eight out of thirty-five patients (23%). Table 2 shows the initial clinical symptoms that prompted the diagnosis. Most preoperative symptoms were mild, whereas 29 of 35 patients (83%) had a grade 1 or 2 on the modified McCormick scale rendering them functionally fully or nearly independent. Only five patients harboring high-grade astrocytomas or carcinoma metastases had a rapidly progressive neurological deficit.

3.2. Surgical and Clinical Outcome

GTR was achieved in 77% of patients who were candidates for this procedure because of the suspected tumor biology. In three patients, we performed a biopsy followed by resection in one case and combined radiation and chemotherapy in two cases with confirmed high-grade gliomas.
New dorsal column-related deficits, i.e., sensory loss and gait ataxia, and motor deficits occurred in 64% and 44% of patients, respectively (preoperatively 38.9% motor deficits, Table 2). At follow up, 25% of patients with dorsal column-related dysfunction and 33% with motor dysfunction recovered to at least their preoperative status. Permanent new motor deficits were observed in 31%, and sensory and gait dysfunction in 43% of patients, respectively. In two patients (5.7%), the preoperative neurological symptoms improved after surgery, but 40% of the cases were clinically independent before surgery and therefore had no possibility of objective clinical improvement. Three patients had further neurologic decline during the follow-up, related to the tumor progression in one case and neurofibromatosis type 2-associated secondary ependymoma manifestation in two cases. The most common deficits were hypesthesia and gait ataxia (Table 3). The results of preoperative, postoperative, and follow-up McCormick scores are summarized in Figure 1. The median preoperative and follow-up McCormick score was 2, with no significant difference in the preoperative and follow-up functional status (p = 0.0897).

3.3. Respiratory Dysfunction

Three patients (8.6%) experienced respiratory complications in the early postoperative course. Two patients with high-grade lesions (glioblastoma WHO°4 and intramedullary metastasis) required prolonged mechanical ventilation and subsequent tracheotomy after the failed weaning. Both of these patients had already presented with higher-graded tetraparesis before surgery. One of these patients was successfully decannulated during the follow-up period of 3 months; the other died during the same hospital stay as the treatment plan was switched to palliative care due to poor prognosis of the melanoma metastasis of the craniocervical junction. A third patient developed respiratory failure mainly due to a bronchial obstruction by a mucus plug. None of the remaining 32 patients (92%) developed any signs of respiratory dysfunction, including pneumonia or dyspnea.
It is possible that respiratory complications and deficits may have occurred after the hospital stay but were not documented. These could include subclinical aspirations, which did not lead to pneumonia requiring antibiotics, desaturation, or tachypnea. Therefore, it is likely that the percentage of C4 paresis has been underestimated in this case.
In addition to the initial three patients mentioned, another trio underwent chest X-rays in order to pinpoint the source of their elevated infection levels. However, none of these individuals exhibited any signs of diaphragm (hemi-)paresis.
Other surgery-related complications included postoperative hemorrhage that required surgery to remove the hematoma in one case and delayed wound healing in two patients who underwent revision surgery. The overall perioperative complication rate, including patients with a postoperative respiratory failure, was 14%. The 30-day mortality was 2.8% (n = 1), whereas this case was not surgery-related.
The preoperative McCormick scale and the WHO grades were the only predictors of the transient (p < 0.001 and p = 0.045, respectively) and permanent postoperative impairment (p < 0.001 and p = 0.009, respectively) (Table 4; Table 5). There were no statistically significant differences when comparing postoperative and follow-up McCormick scores on demographic parameters, duration of symptoms, tumor size, the presence of syringomyelia, or surgery-specific data. Tumor recurrence and operations at multiple spinal levels in NF patients had an unfavorable clinical outcome compared with patients without tumor recurrence and single lesions.

3.4. Case Presentation

A 17-year-old male patient came to our emergency department with a subacute tetraparesis with accentuation on the right side. An MRI scan (Figure 2) revealed a large intramedullary lesion reaching to the upper cervical spinal cord and demonstrating irregular contrast enhancement, highly suspicious for a high-grade tumor. His neurological condition worsened overnight despite intravenous dexamethasone administration, and he developed a C5-level ASIA A quadriplegia by the next morning. We performed a microsurgical GTR of the lesion on the same day, initially hoping for a non-infiltrating tumor entity. The histopathology revealed a diagnosis of a glioblastoma. The patient did not recover from the quadriplegia. Due to the occurred respiratory insufficiency, early tracheotomy was performed 8 days later after the failed weaning. He was sent to neurological rehabilitation. Three months later, he was still quadriplegic, but no longer needed the tracheotomy. He passed away seven months after the surgery.

4. Discussion

4.1. Clinical Outcome

Surgery or at least a biopsy is usually inevitable during the treatment course of IMSCT. GTR is considered the best treatment strategy for the vast majority, as it benefits progression-free survival.
The risk for transient postoperative impairment is known to be significantly high. Previous research on patients with spinal ependymomas reported that more than 60% of patients experience neurological decline immediately after surgery [3,8,9]. In our case series, 77% of the patients developed new neurological deficits, respectively, resulting in a relevant functional decline in 40%, according to a deterioration in the McCormick scale. There is current evidence that the cervical location is an adverse predictive factor for functional outcomes after the surgery of IMSCT. In a large retrospective study reporting on ependymomas of the upper cervical spinal cord, Fei et al. reported on postoperative neurological impairment in 76% of patients and observed a subsequent slow recovery during the next 56 months, still rendering 21% of patients with permanent deterioration [10]. A similar trend of the preoperative, early, and late postoperative neurological status of their patients was reported by another series of intramedullary ependymomas, with a significant deterioration in McCormick scale in the early postoperative period and a recovery to the preoperative condition at the follow-up [11]. However, the difference in the patient’s neurological status was not accompanied by any relevant decline in functional disability, as reflected by the McCormick scale in our study.

4.2. Prognostic Factors for Neurologic Deterioration

We analyzed the predictive factors of postsurgical neurologic deterioration in the early and late follow-up periods. We found that the preoperative McCormick scale grade and the WHO grade were the strongest predictors of postoperative decline. This is consistent with several publications [12,13]. In accordance with our findings and previously conducted studies [10] observing a solid correlation of postoperative neurological decrease with the extent of preoperative disability, we recommend early surgery when patients’ neurological deficits are mild. As observed in our study, only a small proportion of patients improved their functional status compared with the status before surgery (5.7% in our series). However, 40% of the cases were clinically independent before surgery and therefore had no possibility of objective clinical improvement. According to this observation, the wait-and-see strategy, which would inevitably lead to a slow deterioration due to the tumor progression, appears unreasonable: first, retrieving the initial status quo is quite unlikely if the surgery is performed later on and second, the risk for further functional decline is rising during the waiting time.
The other significant criterion for poor neurologic outcomes at follow-up is the WHO grade. This could be explained by the higher neurologic deficits in patients with high-grade astrocytoma and metastases compared with those with ependymomas and hemangioblastomas at presentation. The infiltrating nature of these entities renders surgical treatment less safe. For this reason, the commonly accepted treatment strategy for these tumors is to refrain from GTR and to go for a sample collection via a biopsy to confirm the diagnosis and proceed with adjuvant treatment [5]. Furthermore, intramedullary higher-graded spinal cord gliomas have a poor prognosis despite surgery, radiation, and chemotherapy [5,14]. These treatment options can hardly prevent rapid neurological deterioration and poor overall survival of most patients. Future research on molecular genetics and targeted therapy for these tumors may bring new potential treatment options for these entities [15,16].
Intramedullary metastases occur mainly during the late stages of cancer and are frequently associated with leptomeningeal spread, reflecting an overall poor prognosis. However, surgical therapy may result in a temporary delay of further decline or even the improvement of neurological deficits in some cases. In contrast, the surgery’s only goal is spinal cord decompression by tumor mass debulking or reducing the associated syrinx [17,18].
Injury to the upper cervical spine carries the potential risk of respiratory failure, requiring mechanical ventilation, a prolonged ICU stay, prolonged weaning, an early tracheotomy, increased risk of pulmonary infections, and other associated complications [6]. The respiratory function cannot be monitored by conventional intraoperative monitoring. Nevertheless, though patients with IMSCT seem to be at risk for this adverse clinical course, the incidence appears relatively low. In our series, only three patients (8.6%) developed respiratory failure; in two cases (5.7%), this was clearly caused by upper spinal cord dysfunction. Although respiratory failure appears to be a relatively rare complication, we strongly recommend close monitoring for patients who underwent surgery of IMSCT of the upper spine during the first days after surgery and at least for 24 h due to possible life-threatening consequences.

4.3. Limitations

This study aimed to prove that respiratory issues caused by C4 paresis are not common after surgeries for intramedullary spinal cord tumors. While the results section did mention major complications, it is important to note that this retrospective study could not assess every complication, such as asymptomatic diaphragm (hemi-)paresis, due to a lack of standard postoperative assessments like chest X-rays or dynamic fluoroscopy. Furthermore, we did not assess the benefits of intraoperative ultrasounds (1).
Furthermore, the effects of cortisone during and after surgery may play an important role but were not routinely assessed in our retrospective study.
However, there were other limitations in the research, including a relatively small sample size since these types of tumors and those described are rare. Therefore, statistically significant conclusions about predictive factors for postoperative neurologic decline are difficult to be drawn with certainty from our cohort.

5. Conclusions

Patients with low-grade IMSCT of the upper cervical spine can maintain a good functional status after surgery during the long-term follow-up. However, they should be informed about the high likelihood of transient neurological deficits along with functional decline and temporary disability. Poor preoperative neurological condition and tumor malignancy may contribute to new neurologic deficits. The risk of respiratory deterioration is relatively low but should be considered for postoperative management and rehabilitation.

Author Contributions

Conception and design: V.M.B. and M.W. Acquisition of data: V.M.B. and K.G. Analysis and interpretation of data: V.M.B., M.W. and K.G. Manuscript draft: V.M.B., M.W., K.G. and M.G. Critical revision for important intellectual content: B.M., V.M.B. and M.W. Final approval: V.M.B., M.W. and B.M. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

The presented study meets the ethical standards outlined in the Declaration of Helsinki, ethics approval was obtained and the positive vote was registered under the Number 230/20-S.

Informed Consent Statement

Patient informed consent was not required and waived by our local ethics committee due to the retrospective design of this study.

Data Availability Statement

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Conflicts of Interest

All authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this publication.

References

  1. Samartzis, D.; Gillis, C.C.; Shih, P.; O’Toole, J.E.; Fessler, R.G. Intramedullary Spinal Cord Tumors: Part I-Epidemiology, Pathophysiology, and Diagnosis. Glob. Spine J. 2015, 5, 425–435. [Google Scholar] [CrossRef] [PubMed]
  2. Butenschoen, V.M.; Schwendner, M.; Hubertus, V.; Onken, J.; Koegl, N.; Mohme, T.; Maurer, S.; Boeckh-Behrens, T.; Eicker, S.O.; Thomé, C.; et al. Preoperative angiographic considerations and neurological outcome after surgical treatment of intradural spinal hemangioblastoma: A multicenter retrospective case series. J. Neurooncol. 2023, 161, 107–115. [Google Scholar] [CrossRef] [PubMed]
  3. Wostrack, M.; Ringel, F.; Eicker, S.O.; Jagersberg, M.; Schaller, K.; Kerschbaumer, J.; Thomé, C.; Shiban, E.; Stoffel, M.; Friedrich, B.; et al. Spinal ependymoma in adults: A multicenter investigation of surgical outcome and progression-free survival. J. Neurosurg. Spine 2018, 28, 654–662. [Google Scholar] [CrossRef] [PubMed]
  4. Hersh, A.M.; Antar, A.; Pennington, Z.; Aygun, N.; Patel, J.; Goldsborough, E., 3rd; Porras, J.L.; Elsamadicy, A.A.; Lubelski, D.; Wolinsky, J.P.; et al. Predictors of survival and time to progression following operative management of intramedullary spinal cord astrocytomas. J. Neurooncol. 2022, 158, 117–127. [Google Scholar] [CrossRef] [PubMed]
  5. Butenschoen, V.M.; Hubertus, V.; Janssen, I.K.; Onken, J.; Wipplinger, C.; Mende, K.C.; Eicker, S.O.; Kehl, V.; Thomé, C.; Vajkoczy, P.; et al. Surgical treatment and neurological outcome of infiltrating intramedullary astrocytoma WHO II-IV: A multicenter retrospective case series. J. Neurooncol. 2021, 151, 181–191. [Google Scholar] [CrossRef] [PubMed]
  6. Galeiras Vazquez, R.; Rascado Sedes, P.; Mourelo Farina, M.; Montoto Marques, A.; Ferreiro Velasco, M.E. Respiratory management in the patient with spinal cord injury. Biomed. Res. Int. 2013, 2013, 168757. [Google Scholar] [CrossRef] [PubMed]
  7. McCormick, P.C.; Torres, R.; Post, K.D.; Stein, B.M. Intramedullary ependymoma of the spinal cord. J. Neurosurg. 1990, 72, 523–532. [Google Scholar] [CrossRef] [PubMed]
  8. Gembruch, O.; Chihi, M.; Haarmann, M.; Parlak, A.; Oppong, M.D.; Rauschenbach, L.; Michel, A.; Jabbarli, R.; Ahmadipour, Y.; Sure, U.; et al. Surgical outcome and prognostic factors in spinal cord ependymoma: A single-center, long-term follow-up study. Ther. Adv. Neurol. Disord. 2021, 14, 17562864211055694. [Google Scholar] [CrossRef] [PubMed]
  9. Hussain, I.; Parker, W.E.; Barzilai, O.; Bilsky, M.H. Surgical Management of Intramedullary Spinal Cord Tumors. Neurosurg. Clin. N. Am. 2020, 31, 237–249. [Google Scholar] [CrossRef] [PubMed]
  10. Fei, X.; Jia, W.; Gao, H.; Yang, C.; Li, D.; Qian, Z.; Han, B.; Wang, D.; Xu, Y. Clinical characteristics and surgical outcomes of ependymomas in the upper cervical spinal cord: A single-center experience of 155 consecutive patients. Neurosurg. Rev. 2021, 44, 1665–1673. [Google Scholar] [CrossRef] [PubMed]
  11. Takami, T.; Naito, K.; Yamagata, T.; Ohata, K. Surgical management of spinal intramedullary tumors: Radical and safe strategy for benign tumors. Neurol. Med. Chir. 2015, 55, 317–327. [Google Scholar] [CrossRef] [PubMed]
  12. Bostrom, A.; Kanther, N.C.; Grote, A.; Bostrom, J. Management and outcome in adult intramedullary spinal cord tumours: A 20-year single institution experience. BMC Res. Notes 2014, 7, 908. [Google Scholar] [CrossRef] [PubMed]
  13. Lee, S.M.; Cho, Y.E.; Kwon, Y.M. Neurological outcome after surgical treatment of intramedullary spinal cord tumors. Korean J. Spine 2014, 11, 121–126. [Google Scholar] [CrossRef] [PubMed]
  14. Houten, J.K.; Cooper, P.R. Spinal cord astrocytomas: Presentation, management and outcome. J. Neurooncol. 2000, 47, 219–224. [Google Scholar] [CrossRef] [PubMed]
  15. Azad, T.D.; Jiang, B.; Bettegowda, C. Molecular foundations of primary spinal tumors-implications for surgical management. Ann. Transl. Med. 2019, 7, 222. [Google Scholar] [CrossRef] [PubMed]
  16. Grady, C.; Melnick, K.; Porche, K.; Dastmalchi, F.; Hoh, D.J.; Rahman, M.; Ghiaseddin, A. Glioma Immunotherapy: Advances and Challenges for Spinal Cord Gliomas. Neurospine 2022, 19, 13–29. [Google Scholar] [CrossRef] [PubMed]
  17. Payer, S.; Mende, K.C.; Westphal, M.; Eicker, S.O. Intramedullary spinal cord metastases: An increasingly common diagnosis. Neurosurg. Focus. 2015, 39, E15. [Google Scholar] [CrossRef] [PubMed]
  18. Wostrack, M.; Pape, H.; Kreutzer, J.; Ringel, F.; Meyer, B.; Stoffel, M. Surgical treatment of spinal intradural carcinoma metastases. Acta Neurochir. 2012, 154, 349–357. [Google Scholar] [CrossRef] [PubMed]
Figure 1. Bar graph showing preoperative, postoperative, and follow-up functional status of patients according to the modified McCormick scale.
Figure 1. Bar graph showing preoperative, postoperative, and follow-up functional status of patients according to the modified McCormick scale.
Medicina 59 01754 g001
Figure 2. Magnetic resonance images showing the preoperative MRI scan of the patient with glioblastoma of the spinal cord at C4-Th1 (T2 and T1 with contrast enhancement, 1: sagittal view).
Figure 2. Magnetic resonance images showing the preoperative MRI scan of the patient with glioblastoma of the spinal cord at C4-Th1 (T2 and T1 with contrast enhancement, 1: sagittal view).
Medicina 59 01754 g002
Table 1. Clinical characteristics of 35 patients with intramedullary tumor of the upper cervical spine.
Table 1. Clinical characteristics of 35 patients with intramedullary tumor of the upper cervical spine.
CharacteristicNo. (%) of Mean ± SD
Male20 (57%)
Mean age overall in yrs45 ± 16
Histopathology
Ependymoma (WHO°1–2)22 (62.8%)
Astrocytoma (WHO°2–4)4 (11.4%)
Hemangioblastoma WHO 16 (17.1%)
Metastases2 (5.7%)
Other1 (2.86%)
Patients with neurofibromatosis type 24 (11.4%)
Median duration of symptoms in month3 ± 48
Mean tumor vol in cm31.86 ± 2.58
Presence of syringomyelia8 (23%)
Extent of tumor resection
Gross total resection25 (71.5%)
Subtotal resection7 (20.0%)
Biopsy3 (8.6%)
Table 2. Preoperative symptoms in patients with intramedullary tumor of the upper cervical spine.
Table 2. Preoperative symptoms in patients with intramedullary tumor of the upper cervical spine.
SymptomNo. (%)
Sensoric deficit41.7
Motoric deficit38.9
Pain25.0
Gait ataxia19.4
Table 3. Results of the neurological outcome in all patients. = means no worsening.
Table 3. Results of the neurological outcome in all patients. = means no worsening.
Preoperative DeficitPostoperative DeficitNew Motor DeficitNew Sensory DeficitMotor Deficit at FUSensory Deficit at FU
gait ataxia, hypesthesia sub C5accentuation of hypesthesianoyesNoYes
ASIA DhemiplegiayesnoYesno
intermittent urinary incontinencearm paresis MMT 3/5yesyesYesno
hypesthesiagait ataxianoyeslost to FUlost to FU
mild tetraparesis MMT 4/5aggraviation of distal arm paresisyesyesNono
no deficit (neck pain)hypesthesianoyesNoyes
gait ataxiamild arm paresisyesnoYesno
tingling sensationaggraviation of tingling sensation/hypesthesianoyesnoyes
no deficit (shoulder pain)mild arm paresis, hypesthesiayesyesnono
hemiparesisaggraviation of hemihypesthesianoyesnoyes
hemihypesthesia=nononono
no deficit (vertigo)hemihypesthesianoyeslost to FUlost to FU
mild arm paresisnew hemihypesthesianoyesnono
ASIA Caggraviation of motor deficityesnolost to FUlost to FU
gait ataxiaaggraviation of gait ataxia noyesnono
no deficit (neck pain)hemiparesisyesyesyesyes
no deficit (neck pain)hemiparesisyesyesyesyes
gait ataxia, hypesthesia sub C6ASIA Cyesyeslost to FUlost to FU
no deficit (neck and arm pain)diffuse hypesthesianoyesnono
no deficit (neck and arm pain)diffuse hypesthesianoyesnoyes
gait ataxiamild arm paresisyesyesnoyes
fine motor disability=nonoyesyes
allodynia=nononono
mild arm paresisaccentuation of arm paresisyesnoyesno
mild arm paresisASIA Dyesyesnono
ASIA BASIA Bnononono
no deficit (neck and arm pain)hemihypesthesianoyesnoyes
tingling sensationhemiparesisyesyesyesyes
no deficit (neck and arm pain)=nononono
hypesthesia=nononono
gait ataxia, arm paresisaccentuation of arm paresisyesyesyesyes
hemihypesthesiaaccentuation of hemihypesthesianoyesnono
severe hemiparsis=nonolost to FUlost to FU
ASIA AASIA Anononono
severe hemiparsisaccentuation of severe hemiparesisyesnolost to FUlost to FU
1522912
43%63%31%41%
Table 4. Results of the multivariate regression analysis predicting early neurological impairment. * p < 0.05; *** p < 0.001.
Table 4. Results of the multivariate regression analysis predicting early neurological impairment. * p < 0.05; *** p < 0.001.
Variablep Value
Age0.518
Sex0.257
Tumor vol0.070
Duration of symptoms0.064
Preop McCormick score<0.001 ***
WHO grade0.045 *
Surgical approach0.483
Extension of resection0.415
Syrinx0.335
Loss of potentials in IONM0.016 *
Table 5. Results of the multivariate regression analysis predicting late neurological impairment. * p < 0.05; *** p < 0.001.
Table 5. Results of the multivariate regression analysis predicting late neurological impairment. * p < 0.05; *** p < 0.001.
Variablep Value
Age0.497
Sex0.433
Tumor vol0.151
Duration of symptoms0.373
Preop McCormick score<0.001 ***
WHO grade0.009 *
Surgical approach0.212
Extension of resection0.796
Syrinx0.493
Loss of potentials in IONM0.202
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Goloshchapova, K.; Goldberg, M.; Meyer, B.; Wostrack, M.; Butenschoen, V.M. Neurological Outcome and Respiratory Insufficiency in Intramedullary Tumors of the Upper Cervical Spine. Medicina 2023, 59, 1754. https://doi.org/10.3390/medicina59101754

AMA Style

Goloshchapova K, Goldberg M, Meyer B, Wostrack M, Butenschoen VM. Neurological Outcome and Respiratory Insufficiency in Intramedullary Tumors of the Upper Cervical Spine. Medicina. 2023; 59(10):1754. https://doi.org/10.3390/medicina59101754

Chicago/Turabian Style

Goloshchapova, Kateryna, Maria Goldberg, Bernhard Meyer, Maria Wostrack, and Vicki M. Butenschoen. 2023. "Neurological Outcome and Respiratory Insufficiency in Intramedullary Tumors of the Upper Cervical Spine" Medicina 59, no. 10: 1754. https://doi.org/10.3390/medicina59101754

Article Metrics

Back to TopTop